Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Age \> 18 year old
Confirmed HER2+ metastatic breast cancer
Prior treatment and progression on trastuzumab
Patients must have adequate organ functions
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
You may not be if
Patients who have had surgery within last 2 weeks prior to starting the treatment
Patients who receive concurrent therapy for brain metastases
Impaired heart function or clinically significant heart disease
Ongoing diarrhea
Liver or renal disease with impaired hepatic or renal functions
Concomitant use of any anti-cancer therapy or certain drugs
Female patients who are pregnant or breast feeding
Clareo Health | A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
